Results 21 to 30 of about 29,725 (304)

Activities of Caspofungin, Itraconazole, Posaconazole, Ravuconazole, Voriconazole, and Amphotericin B against 448 Recent Clinical Isolates of Filamentous Fungi

Journal of Clinical Microbiology, 2003
Daniel J. Diekema, S. A. Messer, R. J. Hollis, Ronald N. Jones, Michael A. Pfaller   +4 more
exaly   +2 more sources

Caspofungin MIC Distribution amongst Commonly Isolated Candida Species in a Tertiary Care Centre - An Indian Experience [PDF]

Journal of Clinical and Diagnostic Research, 2016
Introduction: Emergence of Candida species resistant to Amphotericin B and triazole has led to use of echinocandins, mostly caspofungin in the management of invasive candidiasis.
Shashir Wanjare, Rajarshi Gupta, Preeti Mehta   +2 more
doaj   +1 more source

Assessment of Caspofungin use at a Tertiary Teaching Hospital and compliance with IDSA guidelines and FDA labelings

Saudi Pharmaceutical Journal, 2022
Objective: The aim of this study is to evaluate the utilization pattern of Caspofungin in an academic tertiary care hospital in Riyadh, Saudi Arabia. Methods: This is a retrospective study, conducted at King Saud University Medical City, Riyadh, Saudi ...
Abrar F. Alshehri, Thamer A. Almangour, Abdullah A. Alhifany, Abdulaziz Alhossan   +3 more
doaj   +1 more source

Caspofungin Affects Extracellular Vesicle Production and Cargo in Candida auris

Journal of Fungi, 2022
Antifungal resistance has become more frequent, either due to the emergence of naturally resistant species or the development of mechanisms that lead to resistance in previously susceptible species.
R. Amatuzzi, Daniel Zamith-Miranda, I. F. Munhoz da Rocha, A. C. Lucena, Sharon de Toledo Martins, R. Streit, C. Staats, Gabriel Trentin, Fausto Almeida, M. Rodrigues, J. Nosanchuk, Lysangela R Alves   +11 more
semanticscholar   +1 more source

Therapeutic potential of caspofungin combined with trimethoprim-sulfamethoxazole for pneumocystis pneumonia: a pilot study in mice. [PDF]

PLoS ONE, 2013
Pneumocystis pneumonia (PcP) is a major cause of mortality and morbidity in immunocompromised patients. There are limited alternative therapeutic choices to trimethoprim-sulfamethoxazole (TMP-SMX) which is the standard first line therapy/prophylaxis for ...
Maria Luísa Lobo, Francisco Esteves, Bruno de Sousa, Fernando Cardoso, Melanie T Cushion, Francisco Antunes, Olga Matos   +6 more
doaj   +1 more source

Caspofungin pharmacokinetics and probability of target attainment in ICU patients in China

Journal of Global Antimicrobial Resistance, 2021
: Objectives: Effective antifungal therapy is important to reduce mortality in patients with invasive fungal infections (IFIs). Numerous factors affect pharmacokinetic/pharmacodynamic (PK/PD) parameters in critically-ill patients.
Fangyi Li, Minggen Zhou, Zheng Jiao, Zijun Zou, Erqian Yu, Zhijie He   +5 more
doaj   +1 more source

Cost-utility analysis of caspofungin and fluconazole for primary treatment of invasive candidiasis and candidemia in Ethiopia

BMC Health Services Research, 2022
Background Invasive candidiasis and/or candidemia (IC/C) is a common fungal infection leading to significant health and economic losses worldwide. Caspofungin was shown to be more effective than fluconazole in treating inpatients with IC/C. However, cost-
Gebremedhin Beedemariam Gebretekle, Atalay Mulu Fentie, Girma Tekle Gebremariam, Eskinder Eshetu Ali, Daniel Asfaw Erku, Tinsae Alemayehu, Workeabeba Abebe, Beate Sander   +7 more
doaj   +1 more source

Puf4 Mediates Post-transcriptional Regulation of Cell Wall Biosynthesis and Caspofungin Resistance in Cryptococcus neoformans

mBio, 2021
Cryptococcus neoformans is an environmental fungus that causes pulmonary and central nervous system infections. It is also responsible for 15% of AIDS-related deaths.
Murat C. Kalem, H. Subbiah, Jay Leipheimer, Virginia E Glazier, J. Panepinto   +4 more
semanticscholar   +1 more source

Roles of Candida albicans Mig1 and Mig2 in glucose repression, pathogenicity traits, and SNF1 essentiality. [PDF]

, 2020
Metabolic adaptation is linked to the ability of the opportunistic pathogen Candida albicans to colonize and cause infection in diverse host tissues. One way that C.
Filler, Scott G, Huang, Manning Y, Lagree, Katherine, May, Gemma, McManus, C Joel, Mitchell, Aaron P, Solis, Norma V, Woolford, Carol A   +7 more
core   +3 more sources

Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial

Clinical Infectious Diseases, 2020
Background Rezafungin (RZF) is a novel echinocandin exhibiting distinctive pharmacokinetics/pharmacodynamics. STRIVE was a phase 2, double-blind, randomized trial designed to compare the safety and efficacy of RZF once weekly (QWk) to caspofungin (CAS ...
G. Thompson, Á. Soriano, A. Skoutelis, J. Vázquez, P. Honore, J. Horcajada, H. Spapen, M. Bassetti, L. Ostrosky-Zeichner, Anita F. Das, R. Viani, T. Sandison, P. Pappas   +12 more
semanticscholar   +1 more source